Citigroup Boosts Price Target on Allergan (AGN)
On Thursday analysts at Citigroup increased the price target on healthcare company Allergan, Inc. (AGN) citing continuous double digit growth in its core businesses.
The analysts back a “Buy” rating on AGN and now see shares reaching $124. This target suggests a 14% upside to Wednesday’s closing price of $108.53.
Allergan shares were down $1.44, or -1.36%, during morning trading on Thursday. The stock is up about 23% over the past year.
The Bottom Line
Shares of Allergan (AGN) have a dividend yield of 0.19% based on Thursday’s intraday trading price of $107.37 and the company’s annualized dividend payout of 20 cents per share.
Allergan, Inc. (AGN) is not recommended at this time, holding a Dividend.com DARS™ Rating of 3.4 out of 5 stars.
Get FREE Dividend Tips, Updates & MoreWe respect your privacy
- Powerful dividend insights sent every weekday morning
- Gain instant access to actionable investing tips
- Strategically grow your portfolio’s profitability